Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) covers the month of April 2019, with the report signed on April 11, 2019. The filing serves as an Initial Director's Interest Notice submitted to the Australian Securities Exchange (ASX) and incorporated by reference into the company's U.S. registration statements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director interests and does not contain financial performance data.
Material Changes
The primary material change disclosed is the appointment of David Sinclair as a Director of the company, effective April 8, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. It strictly addresses compliance with ASX Listing Rule 3.19A.1 and Section 205G of the Corporations Act regarding the new director's securities interests.
Key Facts for Investor Verification
- New Director Appointment: David Sinclair was appointed as a Director on April 8, 2019.
- Securities Interest: The filing explicitly states that David Sinclair has no relevant interests in securities of the company (neither as a registered holder nor otherwise) at the time of appointment.
- Contractual Interests: The director has no interests in contracts with the company.
- Company Status: The entity is listed on the ASX under the ticker PBT and files annual reports on Form 20-F with the SEC.